For example, inhibitors targeting tumor-specific phosphorylation sites of HuR (e.g., Ser202 (135) or Thr118 (30)) could selectively affect cancer cells without interfering with normal cell mRNA targets. This evidence concerns the gene ELAVL1 and neoplasm.